Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GLUE

Monte Rosa Therapeutics Inc

Dec 13 • 04:00PM ET

7.56

Dollar change -0.23
Percentage change -2.95	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BPMC FATE SRPT PTCT EXEL ADPT SGMO EDIT

| Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC ITOT AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.83	Insider Own	24.81%	Shs Outstand	61.38M	Perf Week	-19.66%
Market Cap	450.75M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	-11.17%	Shs Float	46.20M	Perf Month	-12.40%
Income	-119.39M	PEG	-	EPS next Q	0.18	Inst Own	68.58%	Short Float	23.93%	Perf Quarter	34.52%
Sales	14.97M	P/S	30.11	EPS this Y	61.74%	Inst Trans	12.98%	Short Ratio	4.36	Perf Half Y	97.39%
Book/sh	3.35	P/B	2.26	EPS next Y	-48.89%	ROA	-42.10%	Short Interest	11.05M	Perf Year	51.50%
Cash/sh	4.06	P/C	1.86	EPS next 5Y	-	ROE	-61.23%	52W Range	3.21 - 12.40	Perf YTD	33.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-96.71%	ROI	-48.63%	52W High	-39.03%	Beta	1.39
Dividend TTM	-	Quick Ratio	6.03	Sales past 5Y	0.00%	Gross Margin	47.21%	52W Low	135.51%	ATR (14)	0.91
Dividend Ex-Date	-	Current Ratio	6.03	EPS Y/Y TTM	31.91%	Oper. Margin	-861.30%	RSI (14)	41.82	Volatility	11.99% 10.06%
Employees	133	Debt/Eq	0.21	Sales Y/Y TTM	-	Profit Margin	-797.26%	Recom	1.00	Target Price	15.83
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	58.46%	Payout	-	Rel Volume	0.44	Prev Close	7.79
Sales Surprise	246.57%	EPS Surprise	38.90%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	2.53M	Price	7.56
SMA20	-14.28%	SMA50	-2.13%	SMA200	28.21%	Trades		Volume	1,107,322	Change	-2.95%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wedbush	Outperform	$11
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$18
Oct-13-22	Initiated	UBS	Buy	$22
Aug-15-22	Initiated	Jefferies	Buy	$20
Apr-28-22	Initiated	Credit Suisse	Neutral	$19
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$19
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20

Dec-13-24 07:00AM	Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors (GlobeNewswire)
Dec-11-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer (GlobeNewswire) -9.85%
07:00AM	Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Dec-06-24 07:11AM	Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study (TipRanks) +6.57%
Dec-05-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors (GlobeNewswire)
05:44PM	Loading…
Dec-02-24 05:44PM	Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? (Zacks)
Nov-26-24 07:00AM	Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-24 09:55AM	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet (Zacks) -8.73%
Nov-13-24 07:00AM	Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) -5.48%
Nov-07-24 08:35AM	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice (Zacks)
Oct-30-24 09:55AM	Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade (Zacks)
Oct-29-24 11:50AM	Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler (TipRanks)
10:57AM	Loading…
10:57AM	Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis (GuruFocus.com)
Oct-28-24 05:40PM	Monte Rosa Almost Doubles Up 94% On A Massive Deal With Novartis (Investor's Business Daily) +93.87%
02:26PM	This Biotech Stock Has Doubled Its Value Today Here's Why (Investopedia)
02:10PM	Monte Rosa Stock Doubles Up 127% On A Massive Deal With Novartis (Investor's Business Daily)
08:53AM	Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs (Reuters)
08:46AM	Why Is Monte Rosa Therapeutics Stock Surging On Monday? (Benzinga)
07:33AM	Monte Rosa joins with Novartis in molecular glue drug deal (BioPharma Dive)
07:00AM	Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders (GlobeNewswire)
Oct-23-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors (GlobeNewswire) -8.29%
Aug-28-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.50%
Aug-19-24 07:00AM	Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study (GlobeNewswire)
Aug-08-24 08:15AM	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.25%
07:15AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-08-24 08:36AM	Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day (GlobeNewswire) +6.87%
07:00AM	Loading…
Jun-27-24 07:00AM	Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 (GlobeNewswire) -8.40%
Jun-14-24 08:45AM	Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis (GlobeNewswire)
May-30-24 07:00AM	Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
07:00AM	Monte Rosa Therapeutics Announces Leadership Team Promotions (GlobeNewswire)
May-21-24 07:00AM	Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease (GlobeNewswire) -13.23%
May-16-24 01:09PM	Monte Rosa Therapeutics Prices $100 Million Public Offering (MT Newswires)
07:00AM	Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering (GlobeNewswire)
May-15-24 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-10-24 03:26PM	Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview (GuruFocus.com) -6.37%
May-09-24 01:55PM	GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:21AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-24 04:01PM	Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer (GlobeNewswire) -5.72%
Apr-29-24 10:36AM	UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating (MT Newswires) +5.25%
Apr-10-24 08:50AM	Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why (Zacks) -8.78%
Apr-04-24 09:55AM	Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect? (Zacks)
Mar-22-24 08:50AM	Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-19-24 09:55AM	Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know (Zacks)
Mar-16-24 05:31AM	Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-14-24 01:53PM	GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -8.42%
07:22AM	Monte Rosa Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-24 07:00AM	Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1 Pathway Inhibitor (GlobeNewswire)
Jan-31-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-16-24 09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool) -8.42%
Jan-08-24 07:15AM	Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 (GlobeNewswire) +14.39%
Jan-03-24 07:00AM	Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-23 07:00AM	Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference (GlobeNewswire) -8.31%
Nov-09-23 08:10AM	Monte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic Developments (GuruFocus.com) -10.57%
07:10AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 10:00AM	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases (GlobeNewswire) +6.93%
Oct-27-23 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.20%
Oct-26-23 04:30PM	Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-24-23 09:35AM	Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE) (Zacks)
Oct-17-23 08:03AM	Roche is stuck on molecular glue (BioPharma Dive) -19.80%
07:00AM	Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases (GlobeNewswire)
07:00AM	Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors (GlobeNewswire)
Aug-10-23 07:27AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:15AM	Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-23 07:30AM	Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors (GlobeNewswire)
Jul-16-23 09:50AM	We're Keeping An Eye On Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate (Simply Wall St.)
May-30-23 04:30PM	Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences (GlobeNewswire) +5.16% +13.19%
May-23-23 07:30AM	Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases (GlobeNewswire)
May-11-23 07:50AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:30AM	Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-23 04:30PM	Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023 (GlobeNewswire)
Mar-23-23 07:30AM	Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors (GlobeNewswire)
Mar-16-23 07:52AM	Monte Rosa Therapeutics: Q4 Earnings Snapshot (AP Finance) +7.35%
07:30AM	Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-06-23 08:30AM	Here's Why We're Not Too Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation (Simply Wall St.) -6.94%
Feb-03-23 07:30AM	Monte Rosa Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +15.15%
Jan-25-23 09:55AM	How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46% (Zacks)
Jan-09-23 07:30AM	Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023 (GlobeNewswire) -14.32%
Jan-04-23 07:30AM	Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
Nov-10-22 07:30AM	Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +5.26%
Nov-01-22 07:30AM	Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors (GlobeNewswire)
Oct-31-22 04:30PM	Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +5.99%
Oct-20-22 04:30PM	Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium (GlobeNewswire) +5.28%
Sep-06-22 07:30AM	Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader (GlobeNewswire)
Aug-30-22 08:35AM	We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate (Simply Wall St.) -10.32%
Aug-11-22 07:30AM	Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +5.17%
Jun-14-22 05:16AM	Upcoming 220K-square-foot South End lab project almost fully leased (American City Business Journals) +5.08%
May-11-22 07:30AM	Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -16.03%
Apr-08-22 01:00PM	Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022 (GlobeNewswire)
Mar-29-22 07:30AM	Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates (GlobeNewswire) +16.33%
Mar-23-22 11:32AM	We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-03-22 04:30PM	Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -5.58%
Jan-25-22 07:30AM	Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders (GlobeNewswire) -9.86%

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Versant Venture Capital VI, L.	10% Owner	Oct 28 '24	Sale	9.66	89,990	869,240	2,007,948	Oct 30 04:35 PM
Versant Venture Capital VI, L.	10% Owner	Oct 29 '24	Sale	9.16	67,905	621,801	1,573,453	Oct 30 04:35 PM
Wallace Owen B.	Officer	Oct 28 '24	Proposed Sale	12.00	20,000	240,000		Oct 28 04:05 PM
Versant Venture Capital VI, L.	10% Owner	Sep 20 '24	Sale	6.53	1,132,566	7,395,203	5,099,336	Sep 24 04:40 PM
Versant Venture Capital VI, L.	10% Owner	Sep 11 '24	Sale	6.00	541,897	3,251,382	6,257,218	Sep 13 06:44 PM
Versant Venture Capital VI, L.	10% Owner	Sep 12 '24	Sale	6.00	16,047	96,309	6,241,171	Sep 13 06:44 PM
Versant Venture Capital VI, L.	10% Owner	Sep 13 '24	Sale	6.16	9,269	57,100	6,231,902	Sep 13 06:44 PM
Dunn Edmund	Principal Accounting Officer	Jul 05 '24	Sale	3.83	1,610	6,166	13,944	Jul 09 04:15 PM
Dunn Edmund	Principal Accounting Officer	Jun 03 '24	Sale	4.04	1,207	4,876	15,554	Jun 05 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLUE

Monte Rosa Therapeutics Inc

Upgrade your FINVIZ experience